Therapy of complex I deficiency: Peripheral neuropathy during dichloroacetate therapy
- 68 Downloads
A therapeutic trial with polyvitamins and dichloroacetate (DCA) in combination with thiamine in a 13-year-old girl with complex I deficiency is reported. The polyvitamin therapy included thiamine, riboflavin, ascorbate, coenzyme Q 10 and carnitine. This therapeutic regine was used over a period of 17 months without any effect. Although DCA lowered the lactate concentration in blood and CNS — measured by magnetic resonance spectroscopy — no clinical benefit was achieved. After 20 weeks of DCA therapy a distal polyneuropathy with areflexia developed although 100 mg thiamine daily as comedication was given from the beginning of DCA therapy. Nerve conduction velocity of the peroneal nerve was not detectable, sensible evoked potentials of the tibialis posterious nerve were normal. This side-effect resolved completely within 6 months after omission of DCA. Our observation suggests a direct toxic effect of DCA only on the peripheral nervous system in our patient since several cerebral MRI and magnetic resonance spectroscopy studies showed no abnormalities.
DCA lowers the lactate concentration in children with complex I deficiency of the respiratory chain in a dose of 100 mg/kg body weight without clinical benefit. Reversible peripheral polyneuropathy may develop under DCA therapy despite thiamine medication.
Key wordsComplex I deficiency Polyvitamin therapy Dichloroacetate therapy Polyneuropathy Thiamine administration
magnetic resonance spectroscopy
mitochondrial encephalopathy, lactate acidosis, stroke like episodes
mitochondrial encephalopathy with ragged red fibres
Unable to display preview. Download preview PDF.
- 6.Fischer JC (1985) Mitochondrial myopathies and respiratory chain defects. Dissertation, University of NijmegenGoogle Scholar
- 7.Hammans SR, Morgan-Hughes JA (1994) Mitochondrial myopathies: clinical features, investigation, treatment and genetic counselling. In: Schapira AHV, DiMauro S (ed) Mitochondrial disorders in neurology. Butterworth-Heinemann, Oxford, pp 49–74Google Scholar
- 12.Lilienthal JL, Zierler KL, Folk BP (1950) A reference base and system for analysis of muscle constituents. J Biol Chem 182: 501–508Google Scholar
- 13.McKhann C, Francois B, Evrard P (1980) Longterm use of lower doses of dichloracetate in a child with congenital lactic acidoses. Pediatr Res 14: 167Google Scholar
- 15.Morgan-Hughes JA, Hayes DJ, Cooper M, Clark JB (1985) Mitochondrial myopathies: deficiences localized to complex I and complex III of the mitochondrial respiratory chain. Bio Soc Trans 13: 648–650Google Scholar
- 19.Schon EA (1994) Mitochondrial DNA and the genetics of mitochondrial disease. In: Schapira AHV, DiMauro S (ed) Mitochondrial disorders in neurology, Butterworth-Heinemann, Oxford, pp 31–48Google Scholar
- 22.Stitt M (1985) Citrate synthase. In: Bergmeyer HU (ed) Methods of enzymatic analysis, 3 rd edn. Vol IV, VCH-Verlagsgesellschaft GmbH, Weinheim, pp 353–358Google Scholar
- 24.Williams SR (1992) In vivo proton spectroscopy. Experimental aspects and potential. In: Diehl P, Fluck E, Günther H, Kosfeld R, Seelig J (eds) NMR basic principles and progress. Vol 28. Springer Verlag, Berlin Heidelberg New York, pp 55–72Google Scholar
- 25.Wharton DC, Tzagoloff A (1967) Cytochrome oxidase from beef heart mitochondria. Methods Enzymol 10: 245–250Google Scholar